RELYVRIO/ALBRIOZA will no longer be available for new patients as of April 4, 2024. Patients on therapy as of April 4 in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program.
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
The PHOENIX study of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA™ in Canada) did not meet its prespecified primary or secondary endpoints.
Patient Support Information
If you are currently on RELYVRIO, please contact the Amylyx Care Team.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Driven by People
Latest News
Keep in touch
To stay up to date on Amylyx news, click subscribe.